Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients - iOUTRUN

Study identifier:D3250R00113

ClinicalTrials.gov identifier:NCT05603845

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients Multicountry, multicenter, observational, prospective, primary data, real-world settings

Medical condition

Severe Asthma

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

410

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 20 Feb 2023
Estimated Primary Completion Date: 31 Mar 2025
Estimated Study Completion Date: 31 Mar 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria